Elan finishes Prothena demerger; FDA boss blasts autism treatments;

Conversations on Twitter :

 @FierceBiotech: Add a drop of blood, and this tiny Dx device tests 50 things at once. Story | Follow @FierceBiotech

@JohnCFierce: Halozyme gets $8M upfront and a bunch of potential biobucks in drug delivery collab with Pfizer. Release | Follow @JohnCFierce

@RyanMFierce: Halozyme rebounds with $8M Pfizer biologics pact. More | Follow @RyanMFierce

An FDA advisory panel voted 8-5 against a drug from Hemispherix Biopharma ($HEB) for treating chronic fatigue syndrome. Article

> Irish pharma company Elan ($ELN) has wrapped the demerger of its drug discovery business into a new company called Prothena. Release

> Cubist ($CBST) submitted a supplemental NDA for approval of Entereg for use in speeding GI recovery after bowel surgeries. Release

> Bloomberg reported on treatments for autism that might border on fraud. Item

Pharma News

@FiercePharma: Smaller players looking for expansion deals, too. News | Follow @FiercePharma

> Sanofi animal health deal puts it in India. More

> India vaccinemakers see China undercutting them. Story

> EMA having second thoughts about Merck's Tredaptive. Item

Medical Device News

 @FierceMedDev: St. Jude faces escalation of shareholder lawsuits over Durata leads. Article | Follow @FierceMedDev

@MarkHFierce: Nanostim says it successfully implanted leadless cardiac pacers into 11 patients in the Czech Republic. Major progress. News | Follow @MarkHFierce

 @DamianFierce: Critical Diagnostics has inked distribution deals for its heart test with Quest ($DGX) and LabCorp ($LH). More | Follow @DamianFierce

> Invacare unloads med supplies unit to AssuraMed for $150M. Story

> Cincinnati Children's/Ben-Gurion U back three pediatric device projects. Item

> Illumina soars on fresh Roche buyout rumors. Report

And Finally… Happy holidays! We'll resume breaking news coverage on Dec. 26 and send your next issue of FierceBiotech on Jan. 2.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.